These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23909960)

  • 41. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
    Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
    Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
    Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
    Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S
    Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350
    [No Abstract]   [Full Text] [Related]  

  • 44. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
    Hamada I; Yukutake Y; Morita Y; Ishikawa N; Shimizu K; Wataya-Kaneda M
    J Dermatol; 2024 Jun; 51(6):752-758. PubMed ID: 38619178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial.
    Aitken P; Stanescu I; Boddington L; Mahon C; Fogarasi A; Liao YH; Ivars M; Moreno-Artero E; Trauner D; DeRoos ST; Jancic J; Nikolic M; Balážová P; Price HN; Hadzsiev K; Riney K; Stapleton S; Tollefson MM; Bauer D; Pinková B; Atkinson H
    Br J Dermatol; 2023 Oct; 189(5):520-530. PubMed ID: 37463422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
    Rauktys A; Lee N; Lee L; Dabora SL
    BMC Dermatol; 2008 Jan; 8():1. PubMed ID: 18226258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex.
    Hatano T; Ohno Y; Imai Y; Moritake J; Endo K; Tamari M; Egawa S
    Orphanet J Rare Dis; 2020 Jun; 15(1):133. PubMed ID: 32487130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease].
    Bottyán K; Kemény L; Csoma ZR
    Orv Hetil; 2019 Mar; 160(13):516-520. PubMed ID: 30907099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis.
    Lin YT; Yu CL; Tu YK; Chi CC
    Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.
    Ebrahimi-Fakhari D; Müller CSL; Meyer S; Flotats-Bastardas M; Vogt T; Pföhler C
    Dermatol Ther (Heidelb); 2017 Mar; 7(1):175-179. PubMed ID: 28181194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient.
    Vasani RJ
    Indian J Dermatol; 2015; 60(2):165-9. PubMed ID: 25814705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
    Farges D; Sigg N; Ville D; Martin L
    Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Photodynamic therapy in a patient with facial angiofibromas due to tuberous sclerosis complex.
    Shi M; He S; Chen P; Li Q; Zhu M; Guo J; Jiang L; Wang Q; Peng X; Li S; Li C; Zeng K
    Photodiagnosis Photodyn Ther; 2019 Dec; 28():183-185. PubMed ID: 31398516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Segmental tuberous sclerosis in a patient presenting as unilateral facial angiofibromas, periungual fibromas and Shagreen patch.
    Sener S; Sasmaz S
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):980-2. PubMed ID: 21845812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
    Nathan N; Wang JA; Li S; Cowen EW; Haughey M; Moss J; Darling TN
    J Am Acad Dermatol; 2015 Nov; 73(5):802-8. PubMed ID: 26365597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Topical Rapamycin as Maintenance Treatment after a Single Session of Fractionated CO
    Oh J; Kim J; Lee WJ; Lee JH
    Ann Dermatol; 2019 Oct; 31(5):555-558. PubMed ID: 33911648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical rapamycin combined with calcitriol in treating angiofibromas in tuberous sclerosis complex.
    Lee CH
    Br J Dermatol; 2020 Oct; 183(4):604-606. PubMed ID: 32338383
    [No Abstract]   [Full Text] [Related]  

  • 60. The combination of photodynamic therapy and ultrapulse carbon dioxide laser for facial angiofibromas in tuberous sclerosis complex: A case report.
    Wang B; Yao Y; Huang X; Zhang L; Peng D; Zhang G
    Photodiagnosis Photodyn Ther; 2022 Mar; 37():102725. PubMed ID: 35041984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.